AI assistant
Evotec SE — Regulatory Filings 2014
Apr 24, 2014
151_rns_2014-04-24_06aa338a-f967-4475-a1a0-458b031b364b.html
Regulatory Filings
Open in viewerOpens in your device viewer
News Details
Corporate | 24 April 2014 07:29
Evotec receives first milestone in Roche biomarker collaboration
DGAP-News: Evotec AG / Key word(s): Miscellaneous
24.04.2014 / 07:29
Hamburg, Germany - 24 April 2014: Evotec AG (Frankfurt Stock Exchange: EVT,
TecDAX, ISIN: DE0005664809) today announced the successful achievement of a
milestone in its biomarker alliance with Roche. The milestone was achieved
on the decision by Roche to use a response prediction marker, identified
using Evotec's Proteome Profiling platform, in an extended phase I oncology
trial.
This is the first minor milestone achieved under the collaboration and
licence agreement between Evotec and Roche, signed in 2011, which is part
of the m4 Munich Biotech Cluster Personalized Medicine and Targeted
Therapies initiative funded by the German Federal Ministry of Education and
Research. Under the initial three-year term, Evotec and Roche conduct
biomarker discovery and validation programmes for patient stratification in
targeted cancer therapy. Evotec is eligible for further success-based
payments upon clinical companion diagnostics development.
Dr Mario Polywka, Chief Operating Officer of Evotec AG, commented: "We are
delighted with receiving this milestone and the first validation of our
novel biomarker concept with Roche. I would like to thank everyone involved
in the project to date for the fantastic science they have developed and
for the hard work and determination to see it succeed in a clinical
setting."
About the Proteome Profiling platform
Evotec's Proteome Profiling platform employs high-end mass spectrometry to
identify and quantify thousands of cellular proteins on a global scale.
Unlike immunoassays, Proteome Profiling allows truly unbiased systems-wide
investigation of protein expression in vivo. Comparative analysis of
cellular proteomes not only supports target identification and
mode-of-action studies but also enables the discovery of predictive
biomarkers on the functional protein level.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca,
Roche and UCB. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to
www.evotec.com.
FORWARD-LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, [email protected]
End of Corporate News
24.04.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
264382 24.04.2014